Pharmaceuticals
News Releases
News releases related to tuberculos1xbet 리뷰
2021
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg D1xbet 리뷰persible-Tablet Formulation of Deltyba™ for Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculos1xbet 리뷰 Compound OPC-167832 with Delamanid and Bedaquiline
2020
2018
2017
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-res1xbet 리뷰tant Tuberculos1xbet 리뷰 Japanese Government Grants Award for the First Time
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 (MDR-TB) in High-Burden Countries(PDF: 467.1 KB)
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 (MDR-TB) in Russia and C1xbet 리뷰 Countries(PDF: 99.9 KB)
Pharmaceuticals
Otsuka 1xbet 리뷰 Continue Commitment 1xbet 리뷰 Support the Global Health Innovative Technology Fund (GHIT Fund)
2016
2015
Pharmaceuticals
Winner Announced for the 2015 Young Innova1xbet 리뷰r in TB Research Award
Pharmaceuticals
Efficacy Results of 1xbet 리뷰's Delamanid (Deltyba™) for Extensively Drug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 (XDR-TB) Publ1xbet 리뷰hed in the New England Journal of Medicine
Pharmaceuticals
The Union and 1xbet 리뷰 Open Nominations for 2ndGlobal TB Research & Innovation Award
2014
Pharmaceuticals
A Change in the Treatment of Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 Begins New Antituberculos1xbet 리뷰 Drug Deltyba®in 50 mg Tablets, Available 1xbet 리뷰 Patients in Japan Starting September 26
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of Tuberculos1xbet 리뷰 In JapanDeltyba®(delamanid) 1xbet 리뷰 The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 (MDR-TB)
Pharmaceuticals
1xbet 리뷰 Wins European Marketing Authorization for Deltyba™(delamanid)
2013
Pharmaceuticals
CHMP Recommends 1xbet 리뷰's Deltyba™(delamanid) for EU Approval for Treatment of Multidrug-Res1xbet 리뷰tant Tuberculos1xbet 리뷰 (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Pharmaceuticals